Recurrent vulvovaginal candidosis: focus on the vulva.
Standard
Recurrent vulvovaginal candidosis: focus on the vulva. / Beikert, Florian; Le, Minh T; Koeninger, Angela; Technau, Kristin; Clad, Andreas.
In: MYCOSES, Vol. 54, No. 6, 6, 2011, p. 807-810.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Recurrent vulvovaginal candidosis: focus on the vulva.
AU - Beikert, Florian
AU - Le, Minh T
AU - Koeninger, Angela
AU - Technau, Kristin
AU - Clad, Andreas
PY - 2011
Y1 - 2011
N2 - Recurrent vulvovaginal candidosis is a frequent disease with a serious impact on women's quality of life. Mostly, recurrences are caused by identical Candida strains suggesting C. albicans persistence in the female anogenital area. Objectives of the presented work were to identify the site of C. albicans persistence, to determine clinical symptoms and signs related to C. albicans positive vulvar cultures and to introduce a new therapeutic approach in women with RVVC. Women with an acute, culture-confirmed episode of RVVC at time of visit were included in this prospective case series. Swabs were obtained from both vagina and inter-labial sulcus. Women received a combined 20-day regimen of 100 mg oral fluconazole and ciclopiroxolamin cream topically. Follow-up visits were at 3, 6, 9 and 12 months. Of 139 women, 105 (76%) had at least one C. albicans positive culture from the external vulva. Vulvar positive cultures correlated with pruritus (OR 5.4; P < 0.001), vulvar edema (OR 3.8; P = 0.03) and fissures (OR 2.4; P = 0.03). Recurrence rates were 27%, 33% and 34% (at 6, 9, 12 months, respectively). The external vulva appears to represent a site of C. albicans persistence and source of endogenous re-infection in patients with RVVC. The combined treatment compared favorably with published fluconazole maintenance regimens.
AB - Recurrent vulvovaginal candidosis is a frequent disease with a serious impact on women's quality of life. Mostly, recurrences are caused by identical Candida strains suggesting C. albicans persistence in the female anogenital area. Objectives of the presented work were to identify the site of C. albicans persistence, to determine clinical symptoms and signs related to C. albicans positive vulvar cultures and to introduce a new therapeutic approach in women with RVVC. Women with an acute, culture-confirmed episode of RVVC at time of visit were included in this prospective case series. Swabs were obtained from both vagina and inter-labial sulcus. Women received a combined 20-day regimen of 100 mg oral fluconazole and ciclopiroxolamin cream topically. Follow-up visits were at 3, 6, 9 and 12 months. Of 139 women, 105 (76%) had at least one C. albicans positive culture from the external vulva. Vulvar positive cultures correlated with pruritus (OR 5.4; P < 0.001), vulvar edema (OR 3.8; P = 0.03) and fissures (OR 2.4; P = 0.03). Recurrence rates were 27%, 33% and 34% (at 6, 9, 12 months, respectively). The external vulva appears to represent a site of C. albicans persistence and source of endogenous re-infection in patients with RVVC. The combined treatment compared favorably with published fluconazole maintenance regimens.
KW - Biopsy
KW - Humans
KW - Female
KW - Prospective Studies
KW - Treatment Outcome
KW - Recurrence
KW - Microscopy
KW - Administration, Oral
KW - Administration, Topical
KW - Antifungal Agents/administration & dosage
KW - Candida albicans/isolation & purification
KW - Candidiasis, Vulvovaginal/drug therapy/microbiology/pathology
KW - Fluconazole/administration & dosage
KW - Histocytochemistry
KW - Pyridones/administration & dosage
KW - Skin/pathology
KW - Vulva/microbiology/pathology
KW - Biopsy
KW - Humans
KW - Female
KW - Prospective Studies
KW - Treatment Outcome
KW - Recurrence
KW - Microscopy
KW - Administration, Oral
KW - Administration, Topical
KW - Antifungal Agents/administration & dosage
KW - Candida albicans/isolation & purification
KW - Candidiasis, Vulvovaginal/drug therapy/microbiology/pathology
KW - Fluconazole/administration & dosage
KW - Histocytochemistry
KW - Pyridones/administration & dosage
KW - Skin/pathology
KW - Vulva/microbiology/pathology
M3 - SCORING: Journal article
VL - 54
SP - 807
EP - 810
JO - MYCOSES
JF - MYCOSES
SN - 0933-7407
IS - 6
M1 - 6
ER -